Developer docs
API playgroundTry for free, no card

Search company profiles

Aroa Biosurgery

Full company profile

uuid00051ig

Namestring
Aroa Biosurgery
Legal namestring
Aroa Biosurgery Limited
Websiteurl
aroabio.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Aroa Biosurgery Limited is an ASX-listed (ASX: ARX) New Zealand-based soft-tissue repair medtech company that develops and commercializes regenerative bioscaffolds built on its proprietary AROA ECM™ extracellular matrix platform technology. Its product portfolio includes the Myriad family (Matrix, Morcells, Morcells Fine, Meshed) for complex wounds, trauma, and reconstruction; Endoform™ for acute and chronic wound management; Reinforced Bioscaffolds for hernia repair and abdominal wall reconstruction; and Symphony™, a combination cellular and tissue product (CTP) combining AROA ECM™ with hyaluronic acid, currently advancing through a randomized controlled trial in diabetic foot ulcers.

The company generates revenue primarily through one-time sales of its bioscaffold devices to hospitals, trauma centers, and surgical centers via a direct, sales-led enterprise field motion, with the United States identified as the primary growth geography. In H1 FY26, Aroa reported NZ$19.7 million in revenue (up 33% year-over-year) and its first profitable half-year at NZ$1.8 million EBITDA, with Myriad contributing 44% of product sales. Clinical validation is anchored by the MASTRR study (49 patients across four US Level One trauma centers, zero device-related complications, median 22.5 days to full vascularized tissue coverage) published in the Journal of Trauma and Injury, and the Symphony RCT meeting its primary endpoint in diabetic foot ulcer patients.

Aroa operates with 101-250 employees and targets multiple large addressable markets — a US$450 million US trauma opportunity cited by analysts, a USD 1.33–2.25 billion global regenerative tissue matrix market by 2035 (5.4% CAGR), a USD 2.63 billion biologic hernia repair mesh market by 2030, and a USD 0.84 billion breast reconstruction mesh market by 2030. Four analysts maintain a Strong Buy rating on the stock with an A$0.85 consensus price target versus a current price of A$0.72.

Short descriptiontext

Aroa Biosurgery is an ASX-listed New Zealand medtech company that develops and sells regenerative soft-tissue repair bioscaffolds built on its proprietary AROA ECM™ platform, sold primarily to US hospitals, trauma centers, and surgeons for wound care, reconstruction, and hernia repair applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAuckland, New Zealand
HQ citystring
Auckland
HQ countrystring
New Zealand
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
soft tissue repair, regenerative bioscaffolds, extracellular matrix devices, wound care products, hernia repair mesh
Industry3 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical device / bioscaffold product sales
TypeHardware Sales
Description

Aroa generates revenue primarily through one-time sales of its soft tissue repair bioscaffolds to hospitals and surgical centers. Reported NZ$19.7 million revenue for the half-year period (up 33% year-over-year), with the Myriad product line representing 44% of product sales.

stocksdownunder.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Endoform™
Description

Restorative bioscaffolds for the management of acute and chronic wounds.

aroa.com
+6 more records
Core offering1 text field

Aroa Biosurgery develops, manufactures and commercializes regenerative soft tissue repair bioscaffolds built on its proprietary AROA ECM™ extracellular matrix platform technology. Its portfolio includes the Myriad family of surgical bioscaffolds, Endoform™ for acute and chronic wounds, Reinforced Bioscaffolds for hernia repair and abdominal wall reconstruction, and Symphony™, a combination cellular and tissue product for difficult-to-heal wounds such as diabetic foot ulcers. Products are FDA-cleared and sold to hospitals, trauma centers and surgeons, primarily in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Zero device-related complications and full vascularized tissue coverage in median 22.5 days in the MASTRR study across 49 patients
+3 more records
Product overview1 text field

Aroa Biosurgery offers a platform-plus-modules portfolio centered on its proprietary AROA ECM™ (extracellular matrix) platform technology, which underpins a range of soft tissue repair products aimed at unlocking regenerative healing. The portfolio includes the Myriad family of surgical bioscaffolds (Myriad Matrix™, Myriad Morcells™, Myriad Morcells Fine™, and Myriad Meshed™) for complex wounds, trauma, and reconstruction; Endoform™ for acute and chronic wound management; Reinforced Bioscaffolds targeted at hernia repair and abdominal wall reconstruction; and Symphony™, a combination cellular and tissue product combining AROA ECM™ with hyaluronic acid, under clinical evaluation as a skin substitute for difficult-to-heal wounds such as diabetic foot ulcers.

Product and service7 records
1Myriad Matrix™
CategorySurgical Soft Tissue Bioscaffold
Description

Surgical soft tissue bioscaffold built on the AROA ECM™ platform technology, designed for complex wounds and reconstruction applications including trauma and acute care surgery. Sold to hospitals, trauma centers and surgeons.

2Myriad Morcells™
CategorySurgical Soft Tissue Bioscaffold
Description

Configuration of the AROA ECM™ bioscaffold platform technology for soft tissue repair. Sold to hospitals and surgical centers.

3Myriad Morcells Fine™
CategorySurgical Soft Tissue Bioscaffold
Description

Finer configuration variant of the Myriad Morcells™ bioscaffold offering within the AROA ECM™ platform. Sold to hospitals and surgical centers.

4Myriad Meshed™
CategorySurgical Soft Tissue Bioscaffold
Description

Fenestrated configuration of the AROA ECM™ bioscaffold providing a meshed form factor for soft tissue repair. Sold to hospitals and surgical centers.

5Symphony™
CategoryCellular and Tissue Product (CTP) / Skin Substitute
Description

Combination cellular and tissue product (CTP) comprising AROA ECM™ with hyaluronic acid, under clinical evaluation as a skin substitute for difficult-to-heal wounds including diabetic foot ulcers. Sold to hospitals and wound care specialists.

6Endoform™
CategoryWound Care Bioscaffold
Description

Restorative bioscaffold used in the management of acute and chronic wounds. Sold to hospitals, wound clinics and surgical centers.

7Reinforced Bioscaffolds
CategoryReinforced Surgical Bioscaffold
Description

AROA ECM™-based bioscaffolds designed specifically for hernia repair and abdominal wall reconstruction, providing additional reinforcement for high-tension applications. Sold to hospitals and general/reconstructive surgeons.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public US-listed regenerative medicine company focused on wound care and surgical biologics (e.g., Apligraf, Dermagraft, PuraPly). Directly comparable to Aroa as a competing seller of skin substitutes and regenerative soft-tissue products to US hospitals and wound care clinics.

TypeDirect peer
Description

Public global medical device company with a dedicated Regenerative Technologies portfolio (e.g., Integra Dermal Regeneration Template, AmnioExcel) that competes head-to-head with Aroa's AROA ECM™-based bioscaffolds in wound reconstruction and soft-tissue repair.

TypeDirect peer
Description

Public US-listed regenerative medicine company selling dehydrated amniotic membrane allografts (e.g., EpiFix, AmnioFix) for wound care and surgical applications. Comparable to Aroa in business model, end customers (US hospitals and wound centers), and indication focus (chronic wounds, surgical recovery).

TypeBroad incumbent
Description

Large-cap global medical device incumbent with a substantial Advanced Wound Management portfolio (e.g., Allevyn, PICO). Competes with Aroa for hospital wound care budget and represents a broader, well-funded incumbent that Aroa must displace at US trauma centers.

TypeBroad incumbent
Description

Global Danish medical device company with a dedicated Wound & Skin Care business (e.g., Biatain, Conveen). Comparable to Aroa as a wound care incumbent addressing chronic wounds and skin substitutes in hospitals, though with a much broader product portfolio.

TypeBroad incumbent
Description

Public global medical products company with an Advanced Wound Care franchise (e.g., Aquacel, Foam dressings). Comparable to Aroa as a competitor selling wound management products into US hospitals and a public peer against which Aroa's growth and margins can be benchmarked.

TypeEmerging player
Description

US-based regenerative medicine company marketing MatriStem urinary bladder matrix products for wound management and surgical applications. Closely comparable to Aroa's AROA ECM™ bioscaffold concept (porcine-derived ECM scaffolds) and a direct competitor in complex wound healing.

TypeEmerging player
Description

Non-profit tissue bank that develops and distributes allograft-based wound care and surgical products (e.g., AmnioBand, AlloPatch). Comparable to Aroa in offering biologic wound healing solutions to US hospitals, with overlapping indication coverage.

TypeEmerging player
Description

US-based developer and manufacturer of extracellular matrix products (e.g., Biodesign hernia grafts, Oasis wound matrix). Highly comparable to Aroa in technology approach (ECM-based scaffolds) and indication focus (hernia repair, wound management).

TypeBroad incumbent
Description

Large-cap global medical technology company with a Biosciences and Medical Surgery portfolio that includes wound closure, biosurgery, and tissue products. Comparable to Aroa as a broad incumbent with overlapping biosurgery categories and the scale to influence US hospital procurement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aroa Biosurgery

Regenerative Medical Devicesaroabio.com

Aroa Biosurgery is an ASX-listed New Zealand medtech company that develops and sells regenerative soft-tissue repair bioscaffolds built on its proprietary AROA ECM™ platform, sold primarily to US hospitals, trauma centers, and surgeons for wound care, reconstruction, and hernia repair applications.

What Aroa Biosurgery does

Aroa Biosurgery Limited is an ASX-listed (ASX: ARX) New Zealand-based soft-tissue repair medtech company that develops and commercializes regenerative bioscaffolds built on its proprietary AROA ECM™ extracellular matrix platform technology. Its product portfolio includes the Myriad family (Matrix, Morcells, Morcells Fine, Meshed) for complex wounds, trauma, and reconstruction; Endoform™ for acute and chronic wound management; Reinforced Bioscaffolds for hernia repair and abdominal wall reconstruction; and Symphony™, a combination cellular and tissue product (CTP) combining AROA ECM™ with hyaluronic acid, currently advancing through a randomized controlled trial in diabetic foot ulcers.

The company generates revenue primarily through one-time sales of its bioscaffold devices to hospitals, trauma centers, and surgical centers via a direct, sales-led enterprise field motion, with the United States identified as the primary growth geography. In H1 FY26, Aroa reported NZ$19.7 million in revenue (up 33% year-over-year) and its first profitable half-year at NZ$1.8 million EBITDA, with Myriad contributing 44% of product sales. Clinical validation is anchored by the MASTRR study (49 patients across four US Level One trauma centers, zero device-related complications, median 22.5 days to full vascularized tissue coverage) published in the Journal of Trauma and Injury, and the Symphony RCT meeting its primary endpoint in diabetic foot ulcer patients.

Aroa operates with 101-250 employees and targets multiple large addressable markets — a US$450 million US trauma opportunity cited by analysts, a USD 1.33–2.25 billion global regenerative tissue matrix market by 2035 (5.4% CAGR), a USD 2.63 billion biologic hernia repair mesh market by 2030, and a USD 0.84 billion breast reconstruction mesh market by 2030. Four analysts maintain a Strong Buy rating on the stock with an A$0.85 consensus price target versus a current price of A$0.72.

Aroa Biosurgery firmographics

Firmographics
Name
Aroa Biosurgery
Legal name
Aroa Biosurgery Limited
Website
https://aroabio.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
251–500 employees
Short description
Aroa Biosurgery is an ASX-listed New Zealand medtech company that develops and sells regenerative soft-tissue repair bioscaffolds built on its proprietary AROA ECM™ platform, sold primarily to US hospitals, trauma centers, and surgeons for wound care, reconstruction, and hernia repair applications.
Ownership category
akta.pro rank

Aroa Biosurgery industry classification

Industry
Product category
Regenerative Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAIAG
Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers)

Keywords

  • Soft tissue repair
  • Regenerative bioscaffolds
  • Extracellular matrix devices
  • Wound care products
  • Hernia repair mesh

Where Aroa Biosurgery is headquartered

Location

Headquarters

HQ city
Auckland
HQ country
New Zealand
HQ region
Oceania

Offices1 record

Markets served

Aroa Biosurgery business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Medical device / bioscaffold product sales: Aroa generates revenue primarily through one-time sales of its soft tissue repair bioscaffolds to hospitals and surgical centers. Reported NZ$19.7 million revenue for the half-year period (up 33% year-over-year), with the Myriad product line representing 44% of product sales.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Aroa Biosurgery product offering

Product offering

Core offering

Aroa Biosurgery develops, manufactures and commercializes regenerative soft tissue repair bioscaffolds built on its proprietary AROA ECM™ extracellular matrix platform technology. Its portfolio includes the Myriad family of surgical bioscaffolds, Endoform™ for acute and chronic wounds, Reinforced Bioscaffolds for hernia repair and abdominal wall reconstruction, and Symphony™, a combination cellular and tissue product for difficult-to-heal wounds such as diabetic foot ulcers. Products are FDA-cleared and sold to hospitals, trauma centers and surgeons, primarily in the United States.

Product overview

Aroa Biosurgery offers a platform-plus-modules portfolio centered on its proprietary AROA ECM™ (extracellular matrix) platform technology, which underpins a range of soft tissue repair products aimed at unlocking regenerative healing. The portfolio includes the Myriad family of surgical bioscaffolds (Myriad Matrix™, Myriad Morcells™, Myriad Morcells Fine™, and Myriad Meshed™) for complex wounds, trauma, and reconstruction; Endoform™ for acute and chronic wound management; Reinforced Bioscaffolds targeted at hernia repair and abdominal wall reconstruction; and Symphony™, a combination cellular and tissue product combining AROA ECM™ with hyaluronic acid, under clinical evaluation as a skin substitute for difficult-to-heal wounds such as diabetic foot ulcers.

Differentiator

Problem solved

Functional benefit

Brands

  • Endoform™: Restorative bioscaffolds for the management of acute and chronic wounds.
  • Myriad Matrix™
  • Myriad Morcells™
  • Myriad Morcells Fine™
  • Myriad Meshed™
  • Symphony™
  • Reinforced Bioscaffolds

Products and services

  • Myriad Matrix™ Surgical soft tissue bioscaffold built on the AROA ECM™ platform technology, designed for complex wounds and reconstruction applications including trauma and acute care surgery. Sold to hospitals, trauma centers and surgeons.
  • Myriad Morcells™ Configuration of the AROA ECM™ bioscaffold platform technology for soft tissue repair. Sold to hospitals and surgical centers.
  • Myriad Morcells Fine™ Finer configuration variant of the Myriad Morcells™ bioscaffold offering within the AROA ECM™ platform. Sold to hospitals and surgical centers.
  • Myriad Meshed™ Fenestrated configuration of the AROA ECM™ bioscaffold providing a meshed form factor for soft tissue repair. Sold to hospitals and surgical centers.
  • Symphony™ Combination cellular and tissue product (CTP) comprising AROA ECM™ with hyaluronic acid, under clinical evaluation as a skin substitute for difficult-to-heal wounds including diabetic foot ulcers. Sold to hospitals and wound care specialists.
  • Endoform™ Restorative bioscaffold used in the management of acute and chronic wounds. Sold to hospitals, wound clinics and surgical centers.
  • Reinforced Bioscaffolds AROA ECM™-based bioscaffolds designed specifically for hernia repair and abdominal wall reconstruction, providing additional reinforcement for high-tension applications. Sold to hospitals and general/reconstructive surgeons.

Quantifiable outcome

  • Zero device-related complications and full vascularized tissue coverage in median 22.5 days in the MASTRR study across 49 patients
  • +3 more outcomes

Companies that use Aroa Biosurgery

Customer profile

Segments3 records

Ideal customer profiles3 records

Aroa Biosurgery technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Aroa Biosurgery partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Aroa Biosurgery competitors and assessment

Company assessment

Direct peers

  • Organogenesis Holdings: Public US-listed regenerative medicine company focused on wound care and surgical biologics (e.g., Apligraf, Dermagraft, PuraPly). Directly comparable to Aroa as a competing seller of skin substitutes and regenerative soft-tissue products to US hospitals and wound care clinics.
  • Integra LifeSciences: Public global medical device company with a dedicated Regenerative Technologies portfolio (e.g., Integra Dermal Regeneration Template, AmnioExcel) that competes head-to-head with Aroa's AROA ECM™-based bioscaffolds in wound reconstruction and soft-tissue repair.
  • MiMedx Group: Public US-listed regenerative medicine company selling dehydrated amniotic membrane allografts (e.g., EpiFix, AmnioFix) for wound care and surgical applications. Comparable to Aroa in business model, end customers (US hospitals and wound centers), and indication focus (chronic wounds, surgical recovery).

Broad incumbents

  • Smith & Nephew: Large-cap global medical device incumbent with a substantial Advanced Wound Management portfolio (e.g., Allevyn, PICO). Competes with Aroa for hospital wound care budget and represents a broader, well-funded incumbent that Aroa must displace at US trauma centers.
  • Coloplast: Global Danish medical device company with a dedicated Wound & Skin Care business (e.g., Biatain, Conveen). Comparable to Aroa as a wound care incumbent addressing chronic wounds and skin substitutes in hospitals, though with a much broader product portfolio.
  • ConvaTec: Public global medical products company with an Advanced Wound Care franchise (e.g., Aquacel, Foam dressings). Comparable to Aroa as a competitor selling wound management products into US hospitals and a public peer against which Aroa's growth and margins can be benchmarked.
  • Becton, Dickinson and Company (BD): Large-cap global medical technology company with a Biosciences and Medical Surgery portfolio that includes wound closure, biosurgery, and tissue products. Comparable to Aroa as a broad incumbent with overlapping biosurgery categories and the scale to influence US hospital procurement.

Emerging players

  • ACell: US-based regenerative medicine company marketing MatriStem urinary bladder matrix products for wound management and surgical applications. Closely comparable to Aroa's AROA ECM™ bioscaffold concept (porcine-derived ECM scaffolds) and a direct competitor in complex wound healing.
  • MTF Biologics: Non-profit tissue bank that develops and distributes allograft-based wound care and surgical products (e.g., AmnioBand, AlloPatch). Comparable to Aroa in offering biologic wound healing solutions to US hospitals, with overlapping indication coverage.
  • Cook Biotech: US-based developer and manufacturer of extracellular matrix products (e.g., Biodesign hernia grafts, Oasis wound matrix). Highly comparable to Aroa in technology approach (ECM-based scaffolds) and indication focus (hernia repair, wound management).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Aroa Biosurgery social profiles

Digital presence

Aroa Biosurgery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aroa Biosurgery leadership team

Management profile

Number of profiles

Profiles5 records

Aroa Biosurgery funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aroa Biosurgery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aroa Biosurgery

What does Aroa Biosurgery do?

Aroa Biosurgery develops, manufactures and commercializes regenerative soft tissue repair bioscaffolds built on its proprietary AROA ECM™ extracellular matrix platform technology. Its portfolio includes the Myriad family of surgical bioscaffolds, Endoform™ for acute and chronic wounds, Reinforced Bioscaffolds for hernia repair and abdominal wall reconstruction, and Symphony™, a combination cellular and tissue product for difficult-to-heal wounds such as diabetic foot ulcers. Products are FDA-cleared and sold to hospitals, trauma centers and surgeons, primarily in the United States.

Is Aroa Biosurgery a public or private company?

Aroa Biosurgery is a public company. It is classified as public and is currently operating.

When was Aroa Biosurgery founded?

Aroa Biosurgery was founded in 2008. It employs 251 to 500 people.

Where is Aroa Biosurgery based?

Aroa Biosurgery is headquartered in Auckland, New Zealand, in the Oceania region.

How does Aroa Biosurgery make money?

One revenue line is on record: medical device / bioscaffold product sales.

Who are Aroa Biosurgery's main competitors?

Direct peers on record are Organogenesis Holdings, Integra LifeSciences and MiMedx Group. Broad incumbents are Smith & Nephew, Coloplast, ConvaTec and Becton, Dickinson and Company (BD). Emerging players are ACell, MTF Biologics and Cook Biotech.

Does Aroa Biosurgery have an API?

No public API is recorded for Aroa Biosurgery.

What industry is Aroa Biosurgery in?

Aroa Biosurgery's product category is Regenerative Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAroa Biosurgery Maintains FY27 Revenue Guidance at NZ$ 115-125 MillionAroa Biosurgery maintained FY27 revenue guidance of NZ$115-125 million and normalized EBITDA of NZ$8-11 million. It also signed an exclusive co-promotion with Mölnlycke for Endoform in U.S. post-acute settings, effective October 16, 2026, freeing resources to expand Myriad adoption and pursue Symphony's outpatient wound-care opportunity.TradingViewAroa Biosurgery Limited (ARX) Inks Exclusive U.S. Co-Promotion for EndoformAroa Biosurgery signed an exclusive U.S. co-promotion agreement with Mölnlycke Healthcare US for Endoform, effective Oct. 16, 2026. AROA retains ownership and manufacturing, and its FY27 revenue and EBITDA guidance remain unchanged at NZ$115–125M and NZ$8–11M respectively.Seeking AlphaAroa Biosurgery Limited (AROAF) Discusses Findings and Commercial Impact of Symphony Randomized Controlled Trial TranscriptAroa Biosurgery's CEO and CMO presented findings from the Symphony randomized controlled trial, which treats complex wounds like diabetic and venous ulcers. The company highlighted a U.S. market opportunity exceeding $1 billion, noting recent CMS pricing changes have reset the market but patients still require treatment.Seeking AlphaAroa Biosurgery Limited (AROAF) Discusses Interim Analysis Findings From Ongoing MASTRR Registry Study TranscriptAroa Biosurgery held a conference call on October 6, 2026, to present interim analysis findings from its ongoing MASTRR registry study. CEO Brian Ward and CIO Barnaby May discussed the study's background and results, with surgeon Tracee Short reviewing the analysis. The call also covered commercial implications of the findings.MorningstarPeer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstructionAroa Biosurgery published interim results from its MASTRR Registry in Advances in Therapy, reporting low infection rates with Myriad products across 411 patients and 474 soft tissue defects. Deep tissue infection occurred in 0.7% of patients and superficial in 2.9%, with no adverse events attributed to Myriad. The registry is ongoing with over 550 patients enrolled.AInvestAroa Biosurgery's Clinical Edge Meets a Reinvestment CrossroadsAroa Biosurgery posted its first profitable fiscal year in FY26, with revenue of NZ$103.9 million, up 23% year-over-year. Its Myriad bioscaffold grew 54% and Symphony's diabetic foot ulcer trial met its primary endpoint. The company plans to invest NZ$9 million in FY27 to launch Symphony commercially.Seeking AlphaAroa Biosurgery Limited (AROAF) Shareholder/Analyst Call TranscriptAroa Biosurgery Limited held its 2026 Annual General Meeting, with Chairman James McLean introducing the board of directors and outlining the meeting agenda. CEO Brian Ward was scheduled to present a report on the past year and future outlook, followed by a Q&A session. The formal business of the meeting included resolutions previously provided to shareholders.GurufocusAroa Biosurgery Limited announces the recent appointments of MicAroa Biosurgery Limited announced the appointment of Michael Lynskey as Chief Commercial Officer and Mike Falcon as General Manager – US Commercial to its US commercial team. Lynskey brings over 20 years of advanced wound healing technology experience from Smith+Nephew, while Falcon joins from LifeNet Health with extensive biologics expertise. CEO Brian Ward stated these appointments strengthen the company's ability to execute its growth strategy and capitalize on market opportunities in the US and beyond.YahooAroa Biosurgery Limited announces the recent appointments of Michael Lynskey and Mike Falcon to its US-based commercial team.Aroa Biosurgery Limited announced the appointment of Michael Lynskey as Chief Commercial Officer and Mike Falcon as General Manager – US Commercial to its US commercial team. Lynskey brings over 20 years of experience from Smith+Nephew, Stryker, and Johnson & Johnson in advanced wound healing technology, while Falcon previously held leadership roles at LifeNet Health, Biomet, and Johnson & Johnson. The company stated these appointments are designed to support its growth strategy and capitalize on market opportunities for its Myriad product portfolio and Symphony outpatient product in the United States.PR NewswireAroa Biosurgery Limited announces the recent appointments of Michael Lynskey and Mike Falcon to its US-based commercial team.Aroa Biosurgery Limited announced the appointments of Michael Lynskey as Chief Commercial Officer and Mike Falcon as General Manager – US Commercial to its US-based commercial team. Both appointees bring extensive experience in advanced wound healing technology, with Lynskey joining from Smith+Nephew and Falcon from LifeNet Health, and the company says these appointments support its growth strategy and expansion of its Myriad product portfolio and Symphony outpatient product. Aroa CEO Brian Ward stated these hires strengthen the company's ability to execute its growth strategy in the US and beyond.